RGEN - Repligen Corporation
| Previous Close | 64.05 |
| Open | 63.89 |
| Bid | 62.10 x 800 |
| Ask | 66.90 x 800 |
| Day's Range | 63.87 - 66.59 |
| 52 Week Range | 29.56 - 70.50 |
| Volume | 460,408 |
| Avg. Volume | 487,175 |
| Market Cap | 2.871B |
| Beta (3Y Monthly) | 0.80 |
| PE Ratio (TTM) | 125.62 |
| EPS (TTM) | 0.52 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.00 |
Markit•15 hours agoSee what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGEN
- Investor's Business Daily•yesterday
Trump Trade Comments Boost Dow Jones; These 6 Growth Stocks Take Market Helm
The Dow Jones industrial average is leading another rebound on Wall Street following a sharp pullback in recent days. Chipotle, Attunity, Repligen and McDonald's are acting bullishly.
Markit•3 days agoSee what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGEN
- GlobeNewswire•6 days ago
Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of RGEN earnings conference call or presentation 1-Nov-18 12:30pm GMT
Q3 2018 Repligen Corp Earnings Call
- Investor's Business Daily•8 days ago
Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018
Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.
- Motley Fool•13 days ago
3 Growth Stocks for In-the-Know Investors
An underrated biotech, a boring industrials play, and an intriguing cloud company: Here's why these growth stocks deserve your attention.
- Benzinga•16 days ago
The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...
- Investor's Business Daily•16 days ago
IBD Stock Of The Day Breaks Out On Strong Quarterly Report, Outlook
Repligen is the IBD Stock Of The Day after the bioprocessor broke out for the second time this year on its 15th straight quarter of double-digit sales growth. Shares rose.
- Motley Fool•17 days ago
Here's Why Repligen Rose More Than 16% Today
The under-the-radar biotech reported record quarterly revenue during the third quarter.
- Associated Press•17 days ago
Repligen: 3Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had net income of 10 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The results topped Wall Street expectations. ...
- GlobeNewswire•17 days ago
Repligen Reports Third Quarter 2018 Financial Results
Record quarterly revenue of $49.5 million represents 35% year-over-year growth Revenue guidance raised to $191-$194 million for full year 2018 WALTHAM, Mass., Nov. 01, 2018.
Markit•18 days agoSee what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGEN
Markit•22 days agoSee what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGEN
- GlobeNewswire•27 days ago
Repligen to Report Third Quarter 2018 Financial Results
- Webcast and Conference Call to Be Held Thursday, November 1, 2018 at 8:30 a.m. EDT - WALTHAM, Mass., Oct. 22, 2018 -- Repligen Corporation (NASDAQ:RGEN) today announced that.
- GlobeNewswire•last month
Recent Analysis Shows Repligen, SpartanNash, AZUL SA, Pacira Pharmaceuticals, Ichor, and Scorpio Tankers Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•last month
Repligen Corporation (NASDAQ:RGEN): Earnings To Drop Next Year
Based on Repligen Corporation’s (NASDAQ:RGEN) earnings update in June 2018, analyst consensus outlook appear pessimistic, with profits predicted to drop by -13% next year against the past 5-year average growth Read More...
Markit•2 months agoSee what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGEN
- GlobeNewswire•3 months ago
Recent Analysis Shows STMicroelectronics N.V, Jagged Peak Energy, Inovalon, AC Immune SA, Repligen, and RealNetworks Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STMicroelectronics ...
Markit•3 months agoSee what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGEN
Markit•3 months agoSee what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGEN
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of RGEN earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Repligen Corp Earnings Call
- Zacks•4 months ago
Repligen (RGEN) Misses Q2 Earnings Estimates
Repligen (RGEN) delivered earnings and revenue surprises of -11.11% and 3.62%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
Repligen: 2Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had net income of 6 cents. Earnings, adjusted for one-time gains and costs, were 16 cents per share. The results did not meet Wall ...
